AU2003234929A1 - Therapeutic agent for diabetes - Google Patents
Therapeutic agent for diabetesInfo
- Publication number
- AU2003234929A1 AU2003234929A1 AU2003234929A AU2003234929A AU2003234929A1 AU 2003234929 A1 AU2003234929 A1 AU 2003234929A1 AU 2003234929 A AU2003234929 A AU 2003234929A AU 2003234929 A AU2003234929 A AU 2003234929A AU 2003234929 A1 AU2003234929 A1 AU 2003234929A1
- Authority
- AU
- Australia
- Prior art keywords
- diabetes
- therapeutic agent
- therapeutic
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002143598 | 2002-05-17 | ||
JP2002/143598 | 2002-05-17 | ||
PCT/JP2003/006136 WO2003097064A1 (en) | 2002-05-17 | 2003-05-16 | Therapeutic agent for diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003234929A1 true AU2003234929A1 (en) | 2003-12-02 |
Family
ID=29545025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003234929A Abandoned AU2003234929A1 (en) | 2002-05-17 | 2003-05-16 | Therapeutic agent for diabetes |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2003097064A1 (en) |
AU (1) | AU2003234929A1 (en) |
WO (1) | WO2003097064A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060252780A1 (en) * | 2003-04-25 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | Fused pyrimidine derivatives |
CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
DE102007005045B4 (en) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazine derivatives, process for their preparation and their use as medicines |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
DE102007054497B3 (en) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
DK2470552T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi Sa | NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683698B1 (en) | 2011-03-08 | 2017-10-04 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120050A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001516765A (en) * | 1997-09-12 | 2001-10-02 | ヴォルフ ゲオルグ フォースマン | Compositions for the treatment of diabetes mellitus and obesity |
CA2336412C (en) * | 1998-07-02 | 2007-11-27 | Junichi Shimada | Medicament for treatment of diabetes |
DE60018216T2 (en) * | 1999-12-24 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | CONDENSED PURE DERIVATIVES |
ES2218338T3 (en) * | 2000-04-13 | 2004-11-16 | Pfizer Products Inc. | SYNERGIC EFFECT OF GLIBURIDE AND MILRINONE. |
-
2003
- 2003-05-16 AU AU2003234929A patent/AU2003234929A1/en not_active Abandoned
- 2003-05-16 WO PCT/JP2003/006136 patent/WO2003097064A1/en active Application Filing
- 2003-05-16 JP JP2004505062A patent/JPWO2003097064A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JPWO2003097064A1 (en) | 2005-09-15 |
WO2003097064A1 (en) | 2003-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003234929A1 (en) | Therapeutic agent for diabetes | |
EP2295053B8 (en) | Novel 2H-chromen-2-one-3-carboxamides for medical uses | |
EP1510207A4 (en) | Therapeutic drug for diabetes | |
AU2003301026A1 (en) | Medical wraps | |
AU2003256378A1 (en) | Therapeutic pack | |
AU2003215209A1 (en) | Syringe | |
AU2003278393A1 (en) | New use for pharmaceutical composition | |
AU2002951082A0 (en) | Therapeutic cellular agents | |
AU2003295890A1 (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
AU2003261825A1 (en) | Therapeutic agent for hepatic disease | |
AU2003294318A1 (en) | Therapeutic bioconjugates | |
AU2003259457A1 (en) | Auto-destructible syringe | |
AU2003268672A1 (en) | Drug absorbability improving agents | |
IL165242A0 (en) | Treatment for diabetes | |
AU2003247005A1 (en) | Therapy combination | |
AU2003261903A1 (en) | Blood fluidity improving agent | |
AU2003255372A1 (en) | Medical device | |
AU2003245794A1 (en) | Glycosaminoglycan-dnase combination therapy | |
AU2003215150A1 (en) | Therapeutic compounds | |
AU2003267668A1 (en) | Medical apparatus | |
AU2003223780A1 (en) | Treatment for pompe disease | |
AU2003298582A1 (en) | Therapeutic guanidines | |
AU2003291642A1 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
AU2003243997A1 (en) | Therapeutic agent for brain hemorrhage | |
AU2003255727A1 (en) | Syringes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |